{
    "clinical_study": {
        "@rank": "105695", 
        "arm_group": [
            {
                "arm_group_label": "CHM", 
                "arm_group_type": "Experimental", 
                "description": "Administration of 40mg simvastatin daily, orally for 5 weeks (4-6 weeks window), followed by 5 week (4-6 week window) washout period."
            }, 
            {
                "arm_group_label": "Age-matched controls", 
                "arm_group_type": "Active Comparator", 
                "description": "Administration of 40mg simvastatin daily, orally for 5 weeks (4-6 weeks window), followed by 5 week (4-6 week window) washout period."
            }
        ], 
        "brief_summary": {
            "textblock": "Primary objective: To examine the short-term effects of of simvastatin on the vision on\n      males with choroideremia, evaluated by full-field scotopic threshold testing.  The\n      investigators hypothesize that they will see a reversible decrease in the dark-adapted\n      vision in participants taking simvastatin."
        }, 
        "brief_title": "The Short-term Effects of Simvastatin on the Vision of Males Affected by Choroideremia", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Choroideremia", 
        "condition_browse": {
            "mesh_term": "Choroideremia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participant is willing and able to give informed consent for participation in the\n             study\n\n          -  Male\n\n          -  Diagnosed with choroideremia and in good health\n\n          -  Willing to allow his general practitioner and consultant, if appropriate, to be\n             notified of participation in the study\n\n          -  Over age of 18 years\n\n        Exclusion Criteria:\n\n          -  Female\n\n          -  Significant health disease, disorder, or medication, which, in the opinion of the\n             investigator, would put the patient at risk if he were to take simvastatin\n\n          -  Already taking simvastatin or another statin"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01654562", 
            "org_study_id": "CHM-STATIN"
        }, 
        "intervention": {
            "arm_group_label": [
                "CHM", 
                "Age-matched controls"
            ], 
            "description": "Simvastatin 40mg daily by mouth for 5 weeks (4-6 week window) followed by 5 week washout period (4-6 week window).", 
            "intervention_name": "Simvastatin", 
            "intervention_type": "Drug", 
            "other_name": "Zocor"
        }, 
        "intervention_browse": {
            "mesh_term": "Simvastatin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 7, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Edmonton", 
                    "country": "Canada", 
                    "state": "Alberta", 
                    "zip": "T6G 2R3"
                }, 
                "name": "Ophthalmology Research Office, University of Alberta"
            }, 
            "investigator": {
                "last_name": "Ian M MacDonald, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Repeated Measures Study of Simvastatin on Choroideremia: Simvastatin Intervention and Reversal in Choroideremia Patients and Age-matched Controls.", 
        "overall_contact": {
            "email": "pfreund@ualberta.ca", 
            "last_name": "Paul Freund, MD"
        }, 
        "overall_official": {
            "affiliation": "University of Alberta", 
            "last_name": "Ian M MacDonald, MD, CM", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Full-field scotopic threshold measured at 4-6 weeks after simvastatin administration.", 
            "measure": "Full-field scotopic threshold", 
            "safety_issue": "No", 
            "time_frame": "5 weeks (4-6 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01654562"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Correlation of retinal structure and function with changes in FST after administration of simvastatin.", 
                "measure": "Microperimetry, OCT, fundus autofluorescence, ERG, VA", 
                "safety_issue": "No", 
                "time_frame": "5 weeks (4-6 weeks)"
            }, 
            {
                "description": "Correlation of retinal structure and function with changes in FST after washout of simvastatin.", 
                "measure": "Microperimetry, OCT, fundus autofluorescence, ERG, VA", 
                "safety_issue": "No", 
                "time_frame": "5 weeks (4-6 weeks)"
            }, 
            {
                "description": "Full-field scotopic threshold after washout of simvastatin.", 
                "measure": "Full-field scotopic threshold", 
                "safety_issue": "No", 
                "time_frame": "5 weeks (4-6 weeks)"
            }
        ], 
        "source": "University of Alberta", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Alberta", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}